LTR Pharma Executes U.S. Commercial Agreement with Strive
Key points
- Definitive commercial agreement executed with Strive Specialties Inc.
- Establishes manufacturing, compounding, fulfillment, and distribution framework for ROXUS
- Completes second key pillar of U.S. commercialization strategy
- Provides scalable national manufacturing and fulfillment platform
- Represents a major milestone towards U.S. commercial launch
Full summary
LTR Pharma Limited has executed a definitive Compounding and Supply Agreement with Strive Specialties Inc., a leading U.S. Section 503A compounding pharmacy, converting a previously announced binding Term Sheet into a comprehensive commercial agreement. The agreement establishes the framework for manufacturing, compounding, fulfillment, and nationwide supply of ROXUS in the United States. This agreement, alongside the previously announced agreement with Shed, provides LTR Pharma with the two core commercial pillars required for its U.S. launch: patient acquisition and prescribing through telehealth, and national manufacturing and fulfillment through Strive Pharmacy.
Summary generated by a large language model. Please interpret with care.